Comparative Pharmacology
Head-to-head clinical analysis: SYNERA versus VIVACAINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SYNERA versus VIVACAINE.
SYNERA vs VIVACAINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lidocaine is an amide-type local anesthetic that stabilizes neuronal membranes by inhibiting sodium ion influx, thereby blocking nerve impulse initiation and conduction. Tetracaine is an ester-type local anesthetic that similarly inhibits sodium channels. The combination provides local dermal anesthesia.
VIVACAINE is a local anesthetic that blocks the generation and conduction of nerve impulses by decreasing sodium ion permeability across the neuronal membrane.
Apply 1 patch (70 mg lidocaine and 70 mg tetracaine) to intact skin over the intended venipuncture site or superficial dermatologic procedure site 20-30 minutes prior to procedure; maximum 1 patch per procedure.
5-10 mL of 1% solution (50-100 mg) via submucosal infiltration or nerve block; maximum 500 mg per procedure.
None Documented
None Documented
Lidocaine: 1.5–2 hours; prilocaine: 1–1.5 hours. Terminal half-life similar for both. Note: prolonged in hepatic impairment or neonates.
Terminal elimination half-life: 6–8 hours in healthy adults. In patients with hepatic impairment, half-life may be prolonged up to 12–15 hours; in severe renal impairment (CrCl <30 mL/min), half-life may extend to 10–12 hours.
Renal excretion of lidocaine and prilocaine metabolites: lidocaine <10% unchanged, prilocaine negligible unchanged. Metabolites primarily renal.
Renal excretion of unchanged drug and metabolites accounts for approximately 85–90% of elimination, with about 10–15% excreted in feces via biliary clearance. Less than 2% of the dose is recovered unchanged in urine; the remainder is as glucuronide conjugates and other metabolites.
Category C
Category C
Local Anesthetic
Local Anesthetic